| Literature DB >> 24586577 |
Nahara Anani Martínez-González1, Ryan Tandjung1, Sima Djalali1, Flore Huber-Geismann1, Stefan Markun1, Thomas Rosemann1.
Abstract
BACKGROUND: Physicians' shortage in many countries and demands of high-quality and affordable care make physician-nurse substitution an appealing workforce strategy. The objective of this study is to conduct a systematic review and meta-analysis of randomised controlled trials (RCTs) assessing the impact of physician-nurse substitution in primary care on clinical parameters.Entities:
Mesh:
Year: 2014 PMID: 24586577 PMCID: PMC3933531 DOI: 10.1371/journal.pone.0089181
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1PRISMA Flow diagram – study selection process.
Characteristics of studies included in review.
| Study | Setting | Participants | Nurse group | Physician’s group | Intervention delivered | Outcomes | |||||||||||||||
| First author, y | Location | Design, period | FUP, m | Facilities, n | Included diagnosis | Nurses, n | Patients, N | Mean age (SD), y | Male, % | Phys., n | Patients, N | Mean age (SD), y | Male, % | By | FCA | GDL | 1stC | UV | OC | C, n | reported |
| Fairall, 2012 | ZA 2 | cRCT2, 2008–2010. | 18 | Nurse ART clinic, 31. | HIV/AIDS. | 103 | 6415 | 38 (8.9) | 30 | nr | 6479 | 38 (9.63) | 27 | LN | n | y | n | n | y | >1 | CD4 counts for ART continuation and regimens. |
| Fairall, 2012 | ZA 1 | cRCT1, 2008–2010. | 16–18 | Nurse ART clinic, 31. | HIV/AIDS. | 103 | 6159 | 36 (9.6) | 33 | nr | 4923 | 35 (9.63) | 31 | LN | n | y | n | n | y | >1 | CD4 counts for ART initiation. |
| Houweling, 2011 | NL 4 | RCT, period nr. | 14 | Practice, 1. | DM2. | 2 | 116 | 67.1 (11) | 53 | 5 | 114 | 69.5 (10.6) | 42 | NP | y | y | n | n | y | >1 | BP, TC, GH, TC/HDL ratio. |
| Kuethe, 2011 | NL 3 | RCT, 2006–2008. | 24 | Hospital outpatients, 1; Practice, 18. | Asthma. | nr | 36 | 11.2 (2.9) | 64 | nr | 71 (37 | 11.2 (2.5) | 58 | NP+ | n | y | n | n | y | >1 | PD20, %FEV1, FENO. |
| Voogdt-Pruis 2010 | NL 2 | RCT, 2006–2007. | 12 | Healthcare centre, 6. | CVD, hypertension, hypercholesterolemia. | 6 | 808 | 64 (9.0) | 58 | 25 | 818 | 64 (9.0) | 62 | NP+ | nr | y | n | n | y | >1 | BP, TC. |
| Andryukhin 2010 | RU 1 | RCT, 2006–2009. | 6, 18 | Medical centre practice, 1. | Heart Failure with preserved ejection fraction. | 10 | 50 | 66.5 (3.2) | 27 | 8 | 50 | 68 (4.3) | 34 | NP/LN | n | y | n | n | y | >1 | TC, GH, LDL, Cardiac function/inflammation. |
| Hiss, 2007 | US 2 | RCT, period nr. | 6 | Community, 2; PHD, 1. | DM2. | nr | 95 | 55.7 (13.1) | 32 | 108 | 102 | 57 (11.4) | 35 | NP+ | n | y | n | n | y | >1 | BP, TC, GH. |
| Du Moulin, 2007 | NL 1 | cRCT, period nr. | 12 | nr. | All forms of incontinence. | 1 NP | 38 | 51 (13.0) | 0 | 28 | 13 | 51 (13.0) | 0 | RN | n | y | y | n | y | >1 | Incontinence: frequency and volume. |
| Denver, 2003 | UK 2 | RCT, 2000–2001. | 6 | Nurse clinic hospital based. | DM2, hypertension pre-diagnosis or in receipt of BPLT. | nr | 60 | 58.1 (13.8) | 57 | nr | 60 | 62.4 (9.1) | 70 | NP+ | n | y | n | n | y | >1 | BP, TC, HG, HDL, triglycerides, kidney function. |
| Jarman, 2002 | UK 1 | RCT, 1996–1999. | 24 | Practice, 438 | Parkinson’s Disease. | 9 | 1041 | nr | 57 | nr | 818 | nr | 56 | LN | n | nr | n | n | y | >1 | Stand-up and mobility (tests). |
| Mundinger, 2000 | US 1 | RCT, 1995–1997. | 6–12, 24 | Community clinic, 4; PC clinic, 1. | Asthma, DM, hypertension, or urgent visits. | 7 | 1181 | 44 | 24 | 11 | 800 | 44.9 | 22 | NP | n | nr | y | y | y | >1 | BP, GH, peak flow. |
Legend.
Studies are listed by year (y) of publication, in decreasing order.
Abbreviations: US = United States; NL = The Netherlands; UK = United Kingdom; ZA = South Africa; RU = Russia; RCT = Randomised Controlled Trial; cRCT = cluster Randomised Controlled Trial; FUP = follow-up; m = months; SD = standard deviation; nr = not reported; Phys.: physicians; PHD = Public health department; PC = Primary Care; ART = Antiretroviral Therapy; DM (2) = Diabetes Mellitus (Type 2); CVD = Cardiovascular Disease; BPLT = Blood Pressure Lowering Treatment; NP = nurse practitioner; NP+ = nurse practitioner with higher degree/course; RN = registered nurse; LN = licensed nurse; y = yes; n = no; FCA = full clinical autonomy; GDL = interventions based on clinical guidelines or protocols; 1stC. = 1st contact; UV = urgent visits; OC = on-going care; n (C, n) = number of consultations; BP = blood pressure; TC = total cholesterol; GH = glycosylated haemoglobin; ART = antiretroviral therapy; CD4 = t-cell surface glycoprotein CD4; HDL = high density lipoprotein; LDL = low density lipoprotein; PD20 = provocative dose of methacholine causing a 20% fall in forced expiratory volume in one second (FEV1); FENO = fraction of exhaled nitric oxide.
* start and end year when studies were conducted.
drawn from nine randomly chosen health authority areas.
paediatricians.
general physicians.
63 were for the control group.
** 9 were physicians and 19 were supervisors; intervention delivered following clinical protocols.
2 were nurse practitioners and 8 were (licensed) nurses.
phase I follow-up: 6–12 months; phase II follow-up: 24 months.
Assessment of risk of bias in studies included in review.
| Study | Inclusion &exclusion criteria | Outcome | Sequencegeneration | Allocationconcealment | Blinding | Samplesize | Attrition, % | Funding | ||
| First author, y | Location | 1ry | 2ry | |||||||
| Fairall, 2012 | ZA 2 | ✓ | ✓ | ✓ | A | A | NP | ✓ | ≥20 | G |
| Fairall, 2012 | ZA 1 | ✓ | ✓ | ✓ | A | A | NP | ✓ | ≥20 | G |
| Houweling, 2011 | NL 4 | ✓ | ✓ | ✓ | I | A | NP | ✓ | <20 | G |
| Kuethe, 2011 | NL 3 | ✓ | ✓ | A | A | NP | ✓ | <20 | NR | |
| Voogdt-Pruis, 2010 | NL 2 | ✓ | ✓ | A | U | I | ✓ | <20 | P/Ind. | |
| Andryukhin, 2010 | RU 1 | ✓ | U | I |
| ✓ | ≥20 | None | ||
| Hiss, 2007 | US 2 |
| U | U | NP | NR | <20 | G | ||
| Du Moulin, 2007 | NL 1 | ✓ | ✓ | ✓ | U | U | NP | ✓ | ≥20 | NR |
| Denver, 2003 | UK 2 |
| ✓ | ✓ | I | I | NP | ✓ | <20 | NR |
| Jarman, 2002 | UK 1 | ✓ | ✓ | ✓ | A | A | NP | ✓ | <20 | P/Ind. |
| Mundinger, 2000 | US 1 |
| U | U | NP | ✓ | ≥20 | G | ||
Legend.
Studies are listed by year (y) of publication, in decreasing order. A tick indicates that specific criteria were fulfilled. Blinding: whether patients, care providers and outcome assessors were blinded. Attrition: loss of data (≥20% = significant). Intention-to-treat (ITT): whether trial authors performed analyses (e.g. last value carried forward) to take into account all patients who began the intervention regardless of protocol violations, drop-outs or loss of follow-up [11], [12].
Abbreviations: US = United States; NL = The Netherlands; UK = United Kingdom; ZA = South Africa; RU = Russia; I = Inadequate; A = Adequate; U = Unclear; NP = Not Performed; NR = Not Reported; Funding = Government (G), Industry (Ind.) or Private (P) grant.
* report the inclusion criteria only.
used intention-to-treat (ITT) strategies but type not reported.
adjusted for cluster effect or intra-class cluster correlation.
cluster RCT.
trials for which not all factors tested at baseline were comparable (i.e. ≤10% difference between groups in the factors tested).
reached the least target sample required to achieve power in at least one outcome.
** single blinded, nurses and physicians were not aware of patient allocation.
only patients were blinded.
data analysts were partly blinded.
Huber-White cluster effect approach.
*** intra-class cluster correlation approach not reported.
Figure 2Comparison of blood pressure control between nurse-led care and physician-led care.
Studies are listed in order of decreasing weighted effect size. Abbreviations: mmHg = millimetres of mercury; SD = standard deviation; N = total number of patients in the analysis; WMD = weighted mean differences; CI = confidence interval; df = degrees of freedom; I2 = heterogeneity between trials; FUP = Follow-up; m = months.
Figure 3Comparison of total cholesterol and glycosylated haemoglobin control between nurse-led care and physician-led care.
Studies are listed in order of decreasing weighted effect size. Abbreviations: mmol/L = millimoles per litre of blood; % HbAc1 = percent of glycosylated haemoglobin (of total haemoglobin); SD = standard deviation; N = total number of patients in the analysis; WMD = weighted mean differences; CI = confidence interval; df = degrees of freedom; I2 = heterogeneity between trials; FUP = Follow-up; m = months.
Individual trial estimates from binary data not combined in meta-analyses.
| Study | Outcome | Nurse group | Physician group | Effect estimate | |||||||
| First author, y | Location | Reported | FUP, m | n | N | n | N | RR (95% CI) | p | ||
|
| |||||||||||
| Andryukhin 2010 | RU 1 | TC regression/stay within 4.5 mmol/l. | 6 | 23 | 40 | 10 | 35 | 2.01 (1.12 to 3.62) | 0.02 | ||
| Andryukhin 2010 | RU 1 | LDL regression/stay within 2.5 mmol/l. | 6 | 23 | 40 | 9 | 35 | 2.24 (1.2 to 4.17) | 0.010 | ||
| Andryukhin 2010 | RU 1 | Glucose, decrease/regression/stay within 6 mmol/l. | 6 | 24 | 40 | 22 | 35 | 0.95 (0.67 to 1.37) | 0.800 | ||
|
| |||||||||||
| Andryukhin 2010 | RU 1 | 6MWT exercise capacity decrease/regression. | 6 | 27 | 40 | 7 | 35 | 3.38 (1.68 to 6.77) | 0.001 | ||
| Andryukhin 2010 | RU 1 | NT-proBNP decrease or regression. | 6 | 13 | 17 | 6 | 16 | 2.04 (1.03 to 4.05) | 0.004 | ||
| Andryukhin 2010 | RU 1 | LASI decrease or regression. | 6 | 27 | 40 | 19 | 35 | 1.24 (0.86 to 1.8) | 0.250 | ||
| Andryukhin 2010 | RU 1 | LVEDVI decrease or regression. | 6 | 28 | 40 | 16 | 35 | 1.53 (1.01 to 2.32) | 0.040 | ||
| Andryukhin 2010 | RU 1 | LVMI decrease or regression. | 6 | 17 | 40 | 8 | 35 | 1.86 (0.92 to 3.77) | 0.090 | ||
| Andryukhin 2010 | RU 1 | E/A ratio decrease or regression. | 6 | 19 | 39 | 14 | 34 | 1.18 (0.71 to 1.98) | 0.520 | ||
| Andryukhin 2010 | RU 1 | C-reactive protein levels decrease or regression. | 6 | 24 | 36 | 21 | 32 | 1.02 (0.72 to 1.43) | 0.930 | ||
|
| |||||||||||
| Jarman, 2002 | UK 1 | Mobility stand-up test, unable to stand up or had tohold on. | 24 | 329 | 696 | 247 | 558 | 1.07 (0.95 to 1.21) | 0.940 | ||
| Jarman, 2002 | UK 1 | Bone sustaining fractures during study. | 24 | 92 | 696 | 62 | 558 | 1.19 (0.88 to 1.61) | 0.690 | ||
Legend.
Studies are listed in order of increasing length of follow-up, within each category of outcomes.
Abbreviations: UK = United Kingdom; RU = Russia; FUP = follow-up; m = months; n = number of patients with events or number of events; N = total number of patients per group; RR = relative risk; CI = confidence intervals; LDL = Low Density Lipoprotein; TC = Total Cholesterol; NT-proBNP = N-terminal pro-brain natriuretic peptide; LASI = left atrium size index; LVEDVI = left ventricular end-diastolic volume index; LVMI = left ventricular mass index; E/A ratio = ratio of early (E) to late (A) mitral valve flow velocity; 6MWT = six minute walk test to measure of functional exercise capacity; mmol/l = millimoles per litre.
positive decrease/regression corresponded to less than the upper limit of 95% CI.
Individual trial estimates from continuous data not combined in meta-analyses.
| Study | Outcome | Nurse group | Physician group | Effect estimate | ||||||
| First author, y | Location | Reported | FUP, m | mean (SD) | N | mean (SD) | N | WMD (95% CI) | p | |
|
| ||||||||||
| Denver, 2003 | UK 2 | Mean HDL cholesterol, mmol/l. | 6 | 1.3 (0.3) | 59 | 1.4 (0.5) | 56 | −0.1 (−0.25 to 0.05) | 0.200 | |
| Denver, 2003 | UK 2 | Mean Triglycerides, mmol/l. | 6 | 2.4 (1.7) | 59 | 2.3 (1.4) | 56 | 0.1 (−0.47 to 0.67) | 0.730 | |
| Voogdt-Pruis 2010 | NL 2 | Mean LDL cholesterol, mmol/l. | 12 | 2.9 (1.13) | 218 | 3.1 (1.26) | 270 | −0.2 (−0.41 to 0.01) | 0.06 | |
| Houweling, 2011 | NL 4 | TC/HDL ratio. | 14 | 4.43 (1.1) | 102 | 4.17 (1.2) | 104 | 0.26 (−0.05 to 0.57) | 0.10 | |
|
| ||||||||||
| Mundinger, 2000 | US 1 | Mean peak flow, l/min. | 6 | −297 (108.05) | 107 | −292 (108.05) | 64 | −5 (−38.46 to 28.46) | 0.77 | |
| Kuethe, 2011 | NL 3 | Mean PD20 fall in FEV1. | 12 | −0.12(−0.79 to 1.2) | −0.04(−0.90 to +0.82) | nr | 0.96 | |||
| Kuethe, 2011 | NL 3 | Mean PD20 fall in FEV1. | 24 | 0.75(−0.33 to +1.82) | 0.10(−0.95 to +1.16) | nr | 0.55 | |||
| Kuethe, 2011 | NL 3 | Lung function, % FEV1 of predicted value. | 12 | 3.6 (−0.2 to 7.5) | 0.5 (−3.3 to 4.3) | nr | 0.29 | |||
| Kuethe, 2011 | NL 3 | Lung function, % FEV1 of predicted value. | 24 | 2.5 (−1.1 to 6.2) | 0.9 (−2.7 to 4.5) | nr | 0.57 | |||
| Kuethe, 2011 | NL 3 | Mean p.p.b FENO (3 breath manoeuvres). | 12 | −2.5(−6.6 to 3.4) | 1.6(−2.8 to 7.8) | nr | 0.44 | |||
| Kuethe, 2011 | NL 3 | Mean p.p.b FENO (3 breath manoeuvers). | 24 | −5.1(−9.4 to 0.9) | −2.9(−8.2 to 3.5) | nr | 0.36 | |||
|
| ||||||||||
| Denver, 2003 | UK 2 | >30 mg/day of urinary albumin excretion = complications. | 6 | 39.2 (16.0 to 200.0) | 30.5 (14.5 to 147.2) | nr | nr | |||
| Denver, 2003 | UK 2 | Mean urine sodium excretion, mmol/day. | 6 | 178.7 (103.1) | 59 | 177.3 (87.7) | 56 | 1.4 (−33.52 to 36.32) | 0.940 | |
| Denver, 2003 | UK 2 | Mean serum creatinine, µmol/day. | 6 | 117.6 (40.2) | 59 | 114.7 (37.2) | 56 | 2.9 (−11.25 to 17.05) | 0.690 | |
|
| ||||||||||
| Du Moulin, 2007 | NL 1 | Frequency of incontinence episodes. | 6 | 5.3 (7.4) | 35 | 9.6 (7.7) | 10 | −4.3 (−9.67 to 1.07) | 0.120 | |
| Du Moulin, 2007 | NL 1 | Frequency of incontinence episodes. | 12 | 4.8 (7.5) | 35 | 8.6 (5.6) | 10 | −3.8 (−8.07 to 0.47) | 0.080 | |
| Du Moulin, 2007 | NL 1 | Volume of incontinence episodes, number of pads. | 6 | 5 (3.8) | 35 | 6.4 (3.9) | 10 | −1.4 (−4.13 to 1.33) | 0.310 | |
| Du Moulin, 2007 | NL 1 | Volume of incontinence episodes, number of pads. | 12 | 4.2 (4.2) | 35 | 5.8 (4.1) | 10 | −1.6 (−4.5 to 1.3) | 0.280 | |
|
| ||||||||||
| Fairall, 2012 | ZA 1 | CD4 count for ART initiation. | 12–18 | 161 (175) | 2345 | 141 (161) | 1544 | 20 (9.29 to 30.71) | 0.000 | |
| Fairall, 2012 | ZA 2 | CD4 count for ART continuation and regimens. | 12–18 | 438 (219) | 1733 | 418 (201) | 1691 | 20 (5.93 to 34.07) | 0.005 | |
Legend.
Studies are listed in order of increasing length of follow-up, within each category of outcomes.
Abbreviations: US = United States; NL = The Netherlands; UK = United Kingdom; ZA = South Africa; FUP = follow-up; m = months; N = total number of patients per group; SD = standard deviation; WMD = weighted mean difference; CI = confidence intervals; nr = not reported; ART = Antiretroviral Therapy; FENO = Fraction of Exhaled Nitric Oxide; PD20 = provocative dose of methacholine causing a 20% fall in forced expiratory volume in one second (FEV1); LDL = Low Density Lipoprotein; TC = Total Cholesterol; HDL = High Density Lipoprotein; mmol/l = millimoles per litre; µmol/day = micromoles per day; CD4 = t-cell surface glycoprotein CD4; l/min = litre per minute.
* reported mean (90% CIs) for nurse versus general physician: PD20-FEV1, % predictive value-FEV1, p.p.b FENO.
reported mean (90% CIs) for nurse versus paediatrician: PD20-FEV1, % predictive value-FEV1, p.p.b FENO.
reported the median (interquartile ranges) for nurse and physician groups respectively.
reported between nurse/general physician versus nurse/paediatrician.